Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cecolin 9
- Development stage
- Approved
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Cecolin 9 is a second-generation nonavalent human papillomavirus (HPV) vaccine developed using a recombinant *Escherichia coli* (E. coli) expression system. It is designed to provide protection against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccine is composed of L1 virus-like particles (VLPs) that mimic the structure of the virus to induce high titers of neutralizing antibodies. Developed by Xiamen Innovax Biotech, Cecolin 9 aims to increase global accessibility to high-valent HPV vaccinations, particularly in low- and middle-income countries, by providing a cost-effective alternative to existing nonavalent vaccines like Gardasil 9. Clinical trials have demonstrated its non-inferior immunogenicity and favorable safety profile compared to established 9-valent vaccines.
- Brand names
- Cecolin 9Cecolin9Cecolin-9
- Other names
- 9vHPV vaccine9-valent human papillomavirus vaccineE. coli-produced 9-valent human papillomavirus vaccineNonavalent HPV vaccine
02
Targets
MHC class II-presented human papillomavirus L1 peptide-specific T-cell receptorBCR (Immunoglobulin G B Cell Receptor)HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on Cecolin 9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cecolin 9.